Arndt Vogel· @ArndtVogel · X·· 2 days agoScore70
Body · original
AGITG MASTERPLAN ph II study: mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced PDAC
#ESMO26 #ESMOAmbassadors
👉 Local recurrence: 20 vs 52%
👉 mPFS: 11.3 vs 6.3 mo
👉 mOS: 22 vs 14 mo
🧐Provides evidence for SBRT
@myESMO @ASCO
487 views · 6 likes · 4 reposts · 0 replies
Conference abstracts
3136ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com